Caption Management, LLC Madrigal Pharmaceuticals, Inc. Put Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $2.12 Million - $2.93 Million	10,000 New	10,000 $2.12 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $11.7 Million - $18.2 Million	80,400 Added 402.0%	100,400 $14.7 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $4.08 Million - $6.24 Million	20,000 New	20,000 $4.62 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $4.98 Million - $25.3 Million	85,300 New	85,300 $24.8 Million
Q1 2022 May 13, 2022	BUY	$55.89 - $101.89 $1.4 Million - $2.55 Million	25,000 New	25,000 $2.45 Million
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $1.09 Million - $1.25 Million	-10,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$99.78 - $124.21 $997,800 - $1.24 Million	10,000 New	10,000 $1.19 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $5.57 Million - $7.03 Million	-66,000 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$91.13 - $142.5 $1.01 Million - $1.58 Million	11,100 Added 20.22%	66,000 $6.92 Million
Q1 2019 May 14, 2019	BUY	$103.48 - $143.84 $5.68 Million - $7.9 Million	54,900 New	54,900 $6.88 Million

298

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.81B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.